Clinical Trial Detail

NCT ID NCT04024436
Title A Study of TAS-120 in Patients With Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Taiho Oncology, Inc.
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Futibatinib

Futibatinib

Age Groups: adult senior

Additional content available in CKB BOOST